CNS Drugs

, Volume 22, Issue 6, pp 455–475 | Cite as

Pharmacological Management of Neuropathic Pain Following Spinal Cord Injury

Review Article

Abstract

Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient’s quality of life and is a major specific healthcare problem in its own right. Thus far, there is no cure for the pain and oral pharmaceutical intervention is often inadequate, commonly resulting in a reduction of only 20–30% in pain intensity. Neuropathic pain sensations are characterized by spontaneous persistent pain and a range of abnormally evoked responses, e.g. allodynia (pain evoked by normally non-noxious stimuli) and hyperalgesia (an increased response to noxious stimuli). Neuropathic pain following SCI may be present at or below the level of injury. Oral pharmacological agents used in the treatment of neuropathic pain act either by depressing neuronal activity, by blocking sodium channels or inhibiting calcium channels, by increasing inhibition via GABA agonists, by serotonergic and noradrenergic reuptake inhibition, or by decreasing activation via glutamate receptor inhibition, especially by blocking the NMDA receptor. At present, only ten randomized, double-blind, controlled trials have been performed on oral drug treatment of pain after SCI, the results of most of which were negative. The studies included antidepressants (amitriptyline and trazodone), antiepileptics (gabapentin, pregabalin, lamotrigine and valproate) and mexiletine. Gabapentin, pregabalin and amitriptyline showed a significant reduction in neuropathic pain following SCI. Cannabinoids have been found to relieve other types of central pain, and serotonin noradrenaline reuptake inhibitors as well as opioids relieve peripheral neuropathic pain and may be used to treat patients with SCI pain.

References

  1. 1.
    Lipman AG. Pain as a human right: the 2004 global day against pain. J Pain Palliat Care Pharmacother 2005; 19(3): 85–100PubMedGoogle Scholar
  2. 2.
    Rintala D, Loubser P, Castro J, et al. Chronic pain in a community-based sample of med with spinal cord injury: prevalence, severity, and relationship with impairment, disability, handicap, and subjective well-being. Arch Phys Med Rehabil 1999; 79: 604–14CrossRefGoogle Scholar
  3. 3.
    Widerstrom-Noga EG, Felipe-Cuervo E, Broton JG, et al. Perceived difficulty in dealing with consequences of spinal cord injury. Arch Phys Med Rehabil 1999; 80(5): 580–6PubMedCrossRefGoogle Scholar
  4. 4.
    Ravenscroft A, Ahmed YS, Burnside IG. Chronic pain after SCI: a patient survey. Spinal Cord 2000; 38(10): 611–4PubMedCrossRefGoogle Scholar
  5. 5.
    Levi R, Hultling C, Nash MS, et al. The Stockholm spinal cord injury study: 1. Medical problems in a regional SCI population. Paraplegia 1995; 33(6): 308–15Google Scholar
  6. 6.
    New PW, Lim TC, Hill ST, et al. A survey of pain during rehabilitation after acute spinal cord injury. Spinal Cord 1997; 35(10): 658–63PubMedCrossRefGoogle Scholar
  7. 7.
    Stormer S, Gerner HJ, Gruninger W, et al. Chronic pain/dysaesthesiae in spinal cord injury patients: results of a multicentre study. Spinal Cord 1997; 35(7): 446–55PubMedCrossRefGoogle Scholar
  8. 8.
    Demirel G, Yllmaz H, Gencosmanoglu B, et al. Pain following spinal cord injury. Spinal Cord 1998; 36(1): 25–8PubMedCrossRefGoogle Scholar
  9. 9.
    Siddall PJ, Taylor DA, McClelland JM, et al. Pain report and the relationship of pain to physical factors in the first 6 months following spinal cord injury. Pain 1999; 81(1–2): 187–97PubMedCrossRefGoogle Scholar
  10. 10.
    Siddall PJ, McClelland JM, Rutkowski SB, et al. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003; 103(3): 249–57PubMedCrossRefGoogle Scholar
  11. 11.
    Finnerup NB, Johannesen IL, Sindrup SH, et al. Pain and dysesthesia in patients with spinal cord injury: a postal survey. Spinal Cord 2001; 39(5): 256–62PubMedCrossRefGoogle Scholar
  12. 12.
    Bonica JJ. Introduction: semantic, epidemiologic, and educational issues. In: Casey KL, editor. Pain and central nervous system diseases: the central pain syndromes. 1st ed. New York: Raven Press, 1991Google Scholar
  13. 13.
    Nepomuceno C, Fine PR, Richards JS, et al. Pain in patients with spinal cord injury. Arch Phys Med Rehabil 1979; 60(12): 605–9PubMedGoogle Scholar
  14. 14.
    Siddall PJ. Pain following spinal cord injury. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack’s textbook of pain. 5th ed. London: Elsevier Churchill Livingstone, 2006: 1043–55CrossRefGoogle Scholar
  15. 15.
    Werhagen L, Budh CN, Hultling C, et al. Neuropathic pain after traumatic spinal cord injury: relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord 2004; 42(12): 665–73PubMedCrossRefGoogle Scholar
  16. 16.
    Werhagen L, Hultling C, Molander C. The prevalence of neuropathic pain after non-traumatic spinal cord lesion. Spinal Cord 2007; 45(9): 609–15PubMedCrossRefGoogle Scholar
  17. 17.
    Warms CA, Turner JA, Marshall HM, et al. Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful. Clin J Pain 2002; 18(3): 154–63PubMedCrossRefGoogle Scholar
  18. 18.
    Murphy D, Reid DB. Pain treatment satisfaction in spinal cord injury. Spinal Cord 2001; 39(1): 44–6PubMedCrossRefGoogle Scholar
  19. 19.
    Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997; 48(2): 332–8PubMedCrossRefGoogle Scholar
  20. 20.
    Marchettini P. The burning case of neuropathic pain wording. Pain 2005; 114(3): 313–4PubMedCrossRefGoogle Scholar
  21. 21.
    Putzke JD, Richards JS, Hicken BL, et al. Pain classification following spinal cord injury: the utility of verbal descriptors. Spinal Cord 2002; 40(3): 118–27PubMedCrossRefGoogle Scholar
  22. 22.
    Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Seattle (WA): IASP Press, 1994Google Scholar
  23. 23.
    Siddall PJ, Middleton JW. A proposed algorithm for the management of pain following spinal cord injury. Spinal Cord 2006; 44(2): 67–77PubMedCrossRefGoogle Scholar
  24. 24.
    Hao JX, Xu XJ, Yu YX, et al. Transient spinal cord ischemia induces temporary hypersensitivity of dorsal horn wide dynamic range neurons to myelinated, but not unmyelinated, fiber input. J Neurophysiol 1992; 68(2): 384–91PubMedGoogle Scholar
  25. 25.
    Yezierski RP, Park SH. The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci Lett 1993; 157(1): 115–9PubMedCrossRefGoogle Scholar
  26. 26.
    Christensen MD, Everhart AW, Pickelman JT, et al. Mechanical and thermal allodynia in chronic central pain following spinal cord injury. Pain 1996; 68(1): 97–107PubMedCrossRefGoogle Scholar
  27. 27.
    Drew GM, Siddall PJ, Duggan AW. Responses of spinal neurones to cutaneous and dorsal root stimuli in rats with mechanical allodynia after contusive spinal cord injury. Brain Res 2001; 893(1–2): 59–69PubMedCrossRefGoogle Scholar
  28. 28.
    Hoheisel U, Scheifer C, Trudrung P, et al. Pathophysiological activity in rat dorsal horn neurones in segments rostral to a chronic spinal cord injury. Brain Res 2003; 974(1–2): 134–45PubMedCrossRefGoogle Scholar
  29. 29.
    Finnerup NB, Gyldensted C, Nielsen E, et al. MRI in chronic spinal cord injury patients with and without central pain. Neurology 2003; 61(11): 1569–75PubMedCrossRefGoogle Scholar
  30. 30.
    Finnerup NB, Jensen TS. Spinal cord injury pain: mechanisms and treatment. Eur J Neurol 2004; 11(2): 73–82PubMedCrossRefGoogle Scholar
  31. 31.
    Lenz FA, Weiss N, Ohara S, et al. The role of the thalamus in pain. Suppl Clin Neurophysiol 2004; 57: 50–61PubMedCrossRefGoogle Scholar
  32. 32.
    Hao JX, Xu XJ. Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists. Pain 1996; 66(2–3): 279–85PubMedGoogle Scholar
  33. 33.
    Mills CD, Hulsebosch CE. Increased expression of metabotropic glutamate receptor subtype 1 on spinothalamic tract neurons following spinal cord injury in the rat. Neurosci Lett 2002; 319(2): 59–62PubMedCrossRefGoogle Scholar
  34. 34.
    Mills CD, Johnson KM, Hulsebosch CE. Role of group II and group III metabotropic glutamate receptors in spinal cord injury. Exp Neurol 2002; 173(1): 153–67PubMedCrossRefGoogle Scholar
  35. 35.
    Hains BC, Klein JP, Saab CY, et al. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 2003; 23(26): 8881–92PubMedGoogle Scholar
  36. 36.
    Zhang AL, Hao JX, Seiger A, et al. Decreased GABA immunoreactivity in spinal cord dorsal horn neurons after transient spinal cord ischemia in the rat. Brain Res 1994; 656(1): 187–90PubMedCrossRefGoogle Scholar
  37. 37.
    Drew GM, Siddall PJ, Duggan AW. Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn. Pain 2004; 109(3): 379–88PubMedCrossRefGoogle Scholar
  38. 38.
    Xu XJ, Hao JX, Seiger A, et al. Chronic pain-related behaviors in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain 1994; 56(3): 271–7PubMedCrossRefGoogle Scholar
  39. 39.
    Hains BC, Everhart AW, Fullwood SD, et al. Changes in serotonin, serotonin transporter expression and serotonin denervation supersensitivity: involvement in chronic central pain after spinal hemisection in the rat. Exp Neurol 2002; 175(2): 347–62PubMedCrossRefGoogle Scholar
  40. 40.
    Hao JX, Yu W, Xu XJ, et al. Effects of intrathecal vs. systemic clonidine in treating chronic allodynia-like response in spinally injured rats. Brain Res 1996; 736(1–2): 28–34PubMedCrossRefGoogle Scholar
  41. 41.
    Hains BC, Waxman SG. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci 2006; 26(16): 4308–17PubMedCrossRefGoogle Scholar
  42. 42.
    Oatway MA, Chen Y, Weaver LC. The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 2004; 110(1–2): 259–68PubMedCrossRefGoogle Scholar
  43. 43.
    Siddall PJ, Finnerup NB. Pain following spinal cord injury. In: Cervero F, Jensen TS, editors. Handbook of clinical neurology. London: Elsevier, 2006Google Scholar
  44. 44.
    Hansson P, Kinnman E. Unmasking of neuropathic pain mechanisms in a clinical perspective. Pain Reviews 1996; 3: 272–92Google Scholar
  45. 45.
    Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanismbased classification of pain? Pain 1998; 77(3): 227–9PubMedCrossRefGoogle Scholar
  46. 46.
    Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102(1–2): 1–8PubMedCrossRefGoogle Scholar
  47. 47.
    Finnerup NB, Jensen TS. Mechanisms of disease: mechanismbased classification of neuropathic pain-a critical analysis. Nat Clin Pract Neurol 2006; 2(2): 107–15PubMedCrossRefGoogle Scholar
  48. 48.
    Baron R. Mechanisms of disease: neuropathic pain: a clinical perspective. Nat Clin Pract Neurol 2006; 2(2): 95–106PubMedCrossRefGoogle Scholar
  49. 49.
    Finnerup NB, Sindrup SH, Bach FW, et al. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002; 96(3): 375–83PubMedCrossRefGoogle Scholar
  50. 50.
    Finnerup NB, Biering-Sorensen F, Johannesen IL, et al. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology 2005; 102(5): 1023–30PubMedCrossRefGoogle Scholar
  51. 51.
    Hansson PT, Dickenson AH. Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 2005; 113(3): 251–4PubMedCrossRefGoogle Scholar
  52. 52.
    McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997; 126(9): 712–20PubMedGoogle Scholar
  53. 53.
    Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118(3): 289–305PubMedCrossRefGoogle Scholar
  54. 54.
    Cardenas DD, Warms CA, Turner JA, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002; 96(3): 365–73PubMedCrossRefGoogle Scholar
  55. 55.
    Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007 Dec; 88(12): 1547–60PubMedCrossRefGoogle Scholar
  56. 56.
    Davidoff G, Guarracini M, Roth E, et al. Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study. Pain 1987; 29(2): 151–61PubMedCrossRefGoogle Scholar
  57. 57.
    Levendoglu F, Ogun CO, Ozerbil O, et al. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004; 29(7): 743–51PubMedCrossRefGoogle Scholar
  58. 58.
    Tai Q, Kirshblum S, Chen B, et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 2002; 25(2): 100–5PubMedGoogle Scholar
  59. 59.
    Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67(10): 1792–800PubMedCrossRefGoogle Scholar
  60. 60.
    Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008 May; 136(1–2): 150–7PubMedCrossRefGoogle Scholar
  61. 61.
    Drewes AM, Andreasen A, Poulsen LH. Valproate for treatment of chronic central pain after spinal cord injury: a double-blind cross-over study. Paraplegia 1994; 32(8): 565–9PubMedCrossRefGoogle Scholar
  62. 62.
    Chiou-Tan FY, Tuel SM, Johnson JC, et al. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil 1996; 75(2): 84–7PubMedCrossRefGoogle Scholar
  63. 63.
    Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 1995; 83(5): 1046–54PubMedCrossRefGoogle Scholar
  64. 64.
    Pancrazio JJ, Kamatchi GL, Roscoe AK, et al. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284(1): 208–14PubMedGoogle Scholar
  65. 65.
    Melzack R. The short-form McGill Pain Questionnaire. Pain 1987 Aug; 30(2): 191–7PubMedCrossRefGoogle Scholar
  66. 66.
    Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994 Mar; 23(2): 129–38PubMedGoogle Scholar
  67. 67.
    Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977 Jun 1; 1(3): 385–401CrossRefGoogle Scholar
  68. 68.
    Granger CV, Hamilton BB, Keith RA, et al. Advances in functional assessment for medical rehabilitation. Top Geriatr Rehabil 1986; 1: 59–74Google Scholar
  69. 69.
    Ottenbacher KJ, Hsu Y, Granger CV, et al. The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehabil 1996 Dec; 77(12): 1226–32PubMedCrossRefGoogle Scholar
  70. 70.
    Diener E, Emmons RA, Larsen RJ, et al. The Satisfaction With Life Scale. J Pers Assess 1985 Feb; 49(1): 71–5PubMedCrossRefGoogle Scholar
  71. 71.
    Leijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36(1): 27–36PubMedCrossRefGoogle Scholar
  72. 72.
    Osterberg A, Boivie J. Central pain in multiple sclerosis: a double-blind placebo-controlled trial of amitriptyline and carbamazepine. In: Österberg A, editor. Central pain in multiple sclerosis: clinical characteristics, sensory abnormalities, and treatment. Linköping: University Hospital Linköping, 2005Google Scholar
  73. 73.
    Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75(3): 234–41PubMedCrossRefGoogle Scholar
  74. 74.
    Rasmussen PV, Jensen TS, Sindrup SH, et al. TDM-based imipramine treatment in neuropathic pain. Ther Drug Monit 2004; 26(4): 352–60PubMedCrossRefGoogle Scholar
  75. 75.
    Sindrup SH, Gram LF, Skjold T, et al. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990; 47(4): 509–15PubMedCrossRefGoogle Scholar
  76. 76.
    Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984; 104(3–4): 277–86PubMedCrossRefGoogle Scholar
  77. 77.
    Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975 Sep; 1(3): 277–99PubMedCrossRefGoogle Scholar
  78. 78.
    Zung WW. The measurement of affects: depression and anxiety. Mod Probl Pharmacopsychiatry 1974; 7(0): 170–88PubMedGoogle Scholar
  79. 79.
    Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60(8): 1284–9PubMedCrossRefGoogle Scholar
  80. 80.
    Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110(3): 697–706PubMedCrossRefGoogle Scholar
  81. 81.
    Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116(1–2): 109–18PubMedCrossRefGoogle Scholar
  82. 82.
    Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6(5): 346–56PubMedCrossRefGoogle Scholar
  83. 83.
    Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10(9): 732–47PubMedGoogle Scholar
  84. 84.
    Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995; 56(12): 574–9PubMedGoogle Scholar
  85. 85.
    Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007; 23(1): 175–84PubMedCrossRefGoogle Scholar
  86. 86.
    Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6(1): 108–13PubMedCrossRefGoogle Scholar
  87. 87.
    Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997 Feb; 48(2): 332–8PubMedCrossRefGoogle Scholar
  88. 88.
    Rejas J, Ribera MV, Ruiz M, et al. Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain 2007 Apr; 11(3): 329–40PubMedCrossRefGoogle Scholar
  89. 89.
    Hayes RD, Stewart AL. Sleep measures. In: Stewart AL, Ware Jr JE, editors. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham (NC): Duke University Press, 1992: 235–59Google Scholar
  90. 90.
    Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983 Jun; 67(6): 361–70PubMedCrossRefGoogle Scholar
  91. 91.
    Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): National Institutes of Mental Health, 1976. DHEW publication no. (ADM) 76-338Google Scholar
  92. 92.
    Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004 Dec 14; 63(11): 2104–10PubMedCrossRefGoogle Scholar
  93. 93.
    Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003 Apr 22; 60(8): 1274–83PubMedCrossRefGoogle Scholar
  94. 94.
    Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004 May; 109(1–2): 26–35PubMedCrossRefGoogle Scholar
  95. 95.
    Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 2006; 20(8): 685–93PubMedCrossRefGoogle Scholar
  96. 96.
    Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 1993; 612(1–2): 190–9PubMedCrossRefGoogle Scholar
  97. 97.
    Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56(2): 184–90PubMedCrossRefGoogle Scholar
  98. 98.
    Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007; 128(1–2): 169–79PubMedCrossRefGoogle Scholar
  99. 99.
    Harden RN, Brenman E, Saltz S, et al. Topiramate in the management of spinal cord injury pain: a double-blind, randomized, placebo-controlled pilot study. In: Yezierski RP, Burchiel KJ, editors. Spinal cord injury pain: assessment, mechanisms, management: progress in pain research and management. Vol 23. Seattle (WA): IASP Press, 2002: 393–407Google Scholar
  100. 100.
    Thienel U, Neto W, Schwabe SK, et al. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004; 110(4): 221–31PubMedCrossRefGoogle Scholar
  101. 101.
    Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000; 37(2–3): 103–10PubMedCrossRefGoogle Scholar
  102. 102.
    Strichartz GR, Zhou Z, Sinnott C, et al. Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain. Novartis Found Symp 2002; 241: 189–201; discussion 202-5, 226-32PubMedCrossRefGoogle Scholar
  103. 103.
    Brau ME, Dreimann M, Olschewski A, et al. Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant Na(+) currents in rat sensory neurons. Anesthesiology 2001; 94(1): 137–44PubMedCrossRefGoogle Scholar
  104. 104.
    Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348(13): 1223–32PubMedCrossRefGoogle Scholar
  105. 105.
    Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003; 7(5): 381–6PubMedCrossRefGoogle Scholar
  106. 106.
    Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253PubMedCrossRefGoogle Scholar
  107. 107.
    Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812–9PubMedCrossRefGoogle Scholar
  108. 108.
    Rice A. Cannabinoids. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack’s textbook of pain. 5th ed. London: Elsevier Churchill Livingstone, 2006: 521–39CrossRefGoogle Scholar
  109. 109.
    Siddall PJ, Molloy AR, Walker S, et al. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg 2000; 91(6): 1493–8PubMedCrossRefGoogle Scholar
  110. 110.
    Attal N, Gaude V, Brasseur L, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 2000; 54(3): 564–74PubMedCrossRefGoogle Scholar
  111. 111.
    Kvarnstrom A, Karlsten R, Quiding H, et al. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand 2004; 48(4): 498–506PubMedCrossRefGoogle Scholar
  112. 112.
    Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 1995; 37(6): 1080–7PubMedCrossRefGoogle Scholar
  113. 113.
    Canavero S, Bonicalzi V. Intravenous subhypnotic propofol in central pain: a double-blind, placebo-controlled, crossover study. Clin Neuropharmacol 2004; 27(4): 182–6PubMedCrossRefGoogle Scholar
  114. 114.
    Viola V, Newnham H, Simpson R. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications 2006; 20(1): 34–9PubMedCrossRefGoogle Scholar
  115. 115.
    Norrbrink BC, Kowalski J, Lundeberg T. A comprehensive pain management programme comprising educational, cognitive and behavioural interventions for neuropathic pain following spinal cord injury. J Rehabil Med 2006; 38(3): 172–80CrossRefGoogle Scholar
  116. 116.
    Finnerup NB, Yezierski RP, Sang CN, et al. Treatment of spinal cord injury pain. Pain Clin Updates 2001; 9(2): 1–13Google Scholar
  117. 117.
    Fregni F, Boggio PS, Lima MC, et al. A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain 2006; 122(1–2): 197–209PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Danish Pain Research CenterAarhus University HospitalAarhus CDenmark

Personalised recommendations